1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O

1	Flurazepam	O
2	thus	O
3	appears	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	hypnotic	O
9	drug	O
10	with	O
11	the	O
12	optimum	O
13	dose	O
14	for	O
15	use	O
16	in	O
17	general	O
18	practice	O
19	being	O
20	15	O
21	mg	O
22	at	O
23	night	O
24	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O

1	Intravenous	O
2	administration	O
3	(	O
4	25	O
5	mg	O
6	/	O
7	kg	O
8	)	O
9	of	O
10	carbonic	B
11	anhydrase	I
12	inhibitors	O
13	(	O
14	acetazolamide	O
15	,	O
16	methazolamide	O
17	,	O
18	dichlorphenamide	O
19	,	O
20	sulthiame	O
21	)	O
22	induced	O
23	an	O
24	early	O
25	important	O
26	rise	O
27	of	O
28	cortical	O
29	p	O
30	O2	O
31	,	O
32	which	O
33	is	O
34	not	O
35	dependent	O
36	on	O
37	increase	O
38	of	O
39	p	O
40	O2	O
41	and	O
42	p	O
43	CO2	O
44	and	O
45	decrease	O
46	of	O
47	pH	O
48	in	O
49	arterial	O
50	blood	O
51	.	O

1	Teratological	O
2	study	O
3	of	O
4	etoperidone	O
5	in	O
6	the	O
7	rat	O
8	and	O
9	rabbit	O
10	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	B
5	HI	I
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O

1	Abstracts	O
2	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	Peroxydase	B
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	B
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O

1	Late	O
2	complications	O
3	of	O
4	catheterisation	O
5	for	O
6	intravenous	O
7	nutrition	O
8	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	False	O
2	positive	O
3	amniotic	B
4	fluid	I
5	alpha	I
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	Serum	O
2	-	O
3	ferritin	B
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O

1	In	O
2	2	O
3	subjects	O
4	the	O
5	phytomitogen	O
6	reactivity	O
7	of	O
8	the	O
9	lymphocytes	O
10	was	O
11	improved	O
12	after	O
13	treatment	O
14	.	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Preface	O
2	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	factor	B
6	IX	I
7	activity	O
8	is	O
9	decreased	O
10	in	O
11	coumarin	O
12	treatment	O
13	with	O
14	factor	B
15	IX	I
16	antigen	O
17	remaining	O
18	normal	O
19	.	O

1	The	O
2	concentration	O
3	of	O
4	alpha	B
5	2	I
6	-	I
7	macroglobulin	I
8	,	O
9	alpha	B
10	1	I
11	-	I
12	antitrypsin	I
13	,	O
14	plasminogen	B
15	,	O
16	C3	B
17	-	I
18	complement	I
19	,	O
20	fibrinogen	B
21	degradation	I
22	products	I
23	(	O
24	FDP	B
25	)	O
26	and	O
27	fibrinolytic	O
28	activity	O
29	,	O
30	were	O
31	studied	O
32	in	O
33	the	O
34	aqueous	O
35	humour	O
36	and	O
37	serum	O
38	from	O
39	nine	O
40	patients	O
41	with	O
42	Fuchs	O
43	'	O
44	endothelial	O
45	dystrophy	O
46	,	O
47	17	O
48	patients	O
49	with	O
50	uncomplicated	O
51	senile	O
52	cataract	O
53	and	O
54	in	O
55	the	O
56	secondary	O
57	aqueous	O
58	from	O
59	six	O
60	cataract	O
61	patients	O
62	.	O

1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O

1	Prazosin	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	The	O
2	effect	O
3	of	O
4	CBZ	O
5	and	O
6	DPH	O
7	can	O
8	be	O
9	explained	O
10	by	O
11	interference	O
12	with	O
13	thyroid	O
14	hormone	O
15	binding	O
16	to	O
17	TBG	B
18	combined	O
19	with	O
20	enzyme	O
21	-	O
22	induced	O
23	increased	O
24	metabolic	O
25	clearance	O
26	rate	O
27	of	O
28	thyroid	O
29	hormones	O
30	without	O
31	homeostatic	O
32	maintenance	O
33	of	O
34	premedication	O
35	levels	O
36	of	O
37	FT4	O
38	and	O
39	FT3	O
40	.	O

1	The	O
2	present	O
3	research	O
4	evaluated	O
5	the	O
6	possibility	O
7	that	O
8	polyethylene	O
9	glycol	O
10	400	O
11	(	O
12	PEG	O
13	400	O
14	)	O
15	might	O
16	be	O
17	efficacious	O
18	,	O
19	toxic	O
20	,	O
21	or	O
22	both	O
23	.	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	O
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	Pentobarbital	O
2	(	O
3	1	O
4	,	O
5	3	O
6	,	O
7	10	O
8	,	O
9	and	O
10	17	O
11	.	O
12	5	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	was	O
18	also	O
19	tested	O
20	in	O
21	combination	O
22	with	O
23	rate	O
24	-	O
25	decreasing	O
26	doses	O
27	of	O
28	normeperidine	O
29	(	O
30	17	O
31	.	O
32	5	O
33	mg	O
34	/	O
35	kg	O
36	),	O
37	anileridine	O
38	(	O
39	10	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	alphaprodine	O
45	(	O
46	10	O
47	mg	O
48	/	O
49	kg	O
50	),	O
51	and	O
52	fentanyl	O
53	(	O
54	0	O
55	.	O
56	3	O
57	mg	O
58	/	O
59	kg	O
60	).	O

1	Pb	O
2	foil	O
3	(	O
4	0	O
5	.	O
6	55	O
7	gcm	O
8	-	O
9	2	O
10	)	O
11	provided	O
12	the	O
13	best	O
14	overall	O
15	improvement	O
16	.	O

1	An	O
2	anatomical	O
3	and	O
4	histochemical	O
5	study	O
6	has	O
7	been	O
8	undertaken	O
9	and	O
10	as	O
11	a	O
12	result	O
13	emphasis	O
14	is	O
15	given	O
16	to	O
17	recent	O
18	hypotheses	O
19	that	O
20	suggest	O
21	there	O
22	are	O
23	similarities	O
24	with	O
25	Type	O
26	IV	O
27	glycogen	O
28	storage	O
29	disease	O
30	(	O
31	Andersen	O
32	'	O
33	s	O
34	disease	O
35	)	O
36	which	O
37	,	O
38	although	O
39	clinically	O
40	distinct	O
41	,	O
42	has	O
43	the	O
44	same	O
45	enzyme	O
46	defect	O
47	.	O

1	All	O
2	groups	O
3	were	O
4	tested	O
5	in	O
6	a	O
7	Hebb	O
8	-	O
9	Williams	O
10	maze	O
11	at	O
12	100	O
13	approximately	O
14	10	O
15	days	O
16	of	O
17	age	O
18	.	O

1	Erythromycin	O
2	and	O
3	clindamycin	O
4	resistance	O
5	in	O
6	Corynebacterium	O
7	diphtheriae	O
8	from	O
9	skin	O
10	lesions	O
11	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	O
6	'	O
7	s	O
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	O
16	terms	O
17	M1	O
18	,	O
19	M2	O
20	,	O
21	and	O
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	Variability	O
2	within	O
3	Down	O
4	'	O
5	s	O
6	syndrome	O
7	(	O
8	trisomy	O
9	-	O
10	21	O
11	):	O
12	empirically	O
13	observed	O
14	sex	O
15	differences	O
16	in	O
17	IQs	O
18	.	O

1	VII	O
2	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	indicator	O
19	of	O
20	intravascular	O
21	coagulation	O
22	.	O

1	Eight	O
2	hours	O
3	after	O
4	the	O
5	administration	O
6	of	O
7	colchicine	O
8	,	O
9	the	O
10	serum	B
11	ceruloplasmin	I
12	level	O
13	began	O
14	to	O
15	rise	O
16	again	O
17	in	O
18	female	O
19	rats	O
20	,	O
21	but	O
22	not	O
23	in	O
24	male	O
25	rats	O
26	.	O

1	Radioimmunoassays	O
2	of	O
3	pregnenolone	O
4	,	O
5	progesterone	O
6	,	O
7	dehydroepiandrosterone	O
8	(	O
9	DHA	O
10	)	O
11	16	O
12	alpha	O
13	-	O
14	hydroxy	O
15	-	O
16	DHA	O
17	,	O
18	estriol	O
19	,	O
20	and	O
21	cortisol	O
22	were	O
23	performed	O
24	on	O
25	a	O
26	total	O
27	of	O
28	0	O
29	;	O
30	1	O
31	ml	O
32	;	O
33	of	O
34	fetal	O
35	plasma	O
36	,	O
37	collected	O
38	during	O
39	the	O
40	course	O
41	of	O
42	normal	O
43	vaginal	O
44	delivery	O
45	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O

1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	No	O
2	post	O
3	-	O
4	operative	O
5	haemorrhages	O
6	from	O
7	the	O
8	prostheses	O
9	were	O
10	observed	O
11	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	O
23	EcoRI	B
24	fragment	O
25	.	O

1	Accepting	O
2	arbitrarily	O
3	chosen	O
4	limits	O
5	of	O
6	maximized	O
7	errors	O
8	of	O
9	+/-	O
10	10	O
11	%,	O
12	it	O
13	could	O
14	be	O
15	shown	O
16	that	O
17	the	O
18	system	O
19	did	O
20	not	O
21	work	O
22	acceptably	O
23	when	O
24	the	O
25	mean	O
26	carbon	O
27	dioxide	O
28	concentration	O
29	was	O
30	below	O
31	1	O
32	.	O
33	5	O
34	vol	O
35	.%	O
36	within	O
37	the	O
38	fresh	O
39	gas	O
40	flow	O
41	rates	O
42	(	O
43	2	O
44	.	O
45	2	O
46	--	O
47	7	O
48	.	O
49	7	O
50	1	O
51	min	O
52	-	O
53	1	O
54	)	O
55	and	O
56	the	O
57	range	O
58	of	O
59	minute	O
60	ventilation	O
61	(	O
62	4	O
63	--	O
64	10	O
65	1	O
66	min	O
67	-	O
68	1	O
69	)	O
70	employed	O
71	.	O

1	SV	O
2	increased	O
3	less	O
4	in	O
5	SHR	O
6	,	O
7	mainly	O
8	reflecting	O
9	the	O
10	reduced	O
11	diastolic	O
12	compliance	O
13	of	O
14	the	O
15	hypertrophied	O
16	SHR	O
17	left	O
18	ventricle	O
19	and	O
20	the	O
21	consequent	O
22	rightward	O
23	shift	O
24	of	O
25	its	O
26	Frank	O
27	-	O
28	Starling	O
29	curve	O
30	.	O

1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Patulin	O
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O

1	Polyglactin	O
2	910	O
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	The	O
2	incidence	O
3	of	O
4	DNCB	O
5	reactions	O
6	was	O
7	78	O
8	per	O
9	cent	O
10	for	O
11	Stage	O
12	I	O
13	and	O
14	II	O
15	cancers	O
16	(	O
17	37	O
18	patinets	O
19	),	O
20	73	O
21	per	O
22	cent	O
23	for	O
24	resectable	O
25	Stage	O
26	III	O
27	cancer	O
28	(	O
29	22	O
30	patients	O
31	),	O
32	and	O
33	66	O
34	per	O
35	cent	O
36	in	O
37	patients	O
38	with	O
39	unresectable	O
40	or	O
41	inoperable	O
42	Stage	O
43	III	O
44	cancer	O
45	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	Sixteen	O
2	other	O
3	normal	O
4	subjects	O
5	with	O
6	2	O
7	g	O
8	of	O
9	Metyrapone	O
10	are	O
11	best	O
12	responses	O
13	.	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	O
6	for	O
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	O
37	,	O
38	spatial	O
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	Ectopic	O
2	ACTH	B
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	B
18	contents	O
19	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	serum	B
7	LH	I
8	and	O
9	chronological	O
10	or	O
11	bone	O
12	age	O
13	in	O
14	this	O
15	age	O
16	group	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	the	O
22	correlation	O
23	found	O
24	is	O
25	not	O
26	due	O
27	to	O
28	age	O
29	-	O
30	related	O
31	parallel	O
32	phenomena	O
33	.	O

1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O

1	Efforts	O
2	were	O
3	made	O
4	to	O
5	determine	O
6	the	O
7	amount	O
8	of	O
9	time	O
10	required	O
11	for	O
12	kidney	O
13	lesions	O
14	to	O
15	develop	O
16	and	O
17	,	O
18	if	O
19	possible	O
20	,	O
21	to	O
22	delineate	O
23	the	O
24	potential	O
25	site	O
26	of	O
27	action	O
28	of	O
29	PBB	O
30	.	O

1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O

1	Distribution	O
2	and	O
3	correlations	O
4	of	O
5	serum	O
6	uric	O
7	-	O
8	acid	O
9	in	O
10	two	O
11	French	O
12	adult	O
13	populations	O
14	:	O
15	13	O
16	,	O
17	885	O
18	men	O
19	and	O
20	6	O
21	,	O
22	861	O
23	women	O

1	The	O
2	incidence	O
3	of	O
4	hepatitis	B
5	B	I
6	antigen	I
7	following	O
8	transfusion	O
9	was	O
10	about	O
11	2	O
12	.	O
13	8	O
14	per	O
15	cent	O
16	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	Treatment	O
2	of	O
3	2	O
4	patients	O
5	with	O
6	pseudohypoparathyroidism	O
7	type	O
8	I	O
9	with	O
10	vitamin	O
11	-	O
12	D	O
13	-	O
14	3	O
15	and	O
16	1	O
17	alpha	O
18	-	O
19	Hydroxycholecalciferol	O
20	consecutively	O
21	resulted	O
22	in	O
23	a	O
24	nonuniform	O
25	response	O
26	with	O
27	regard	O
28	to	O
29	the	O
30	normalisation	O
31	of	O
32	serum	O
33	-	O
34	calcium	O
35	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	O
19	-	O
20	block	O
21	group	O
22	.	O
23	beta	O
24	-	O
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	O
78	played	O
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	O
21	vitro	O
22	.	O

1	Modulation	O
2	of	O
3	25	B
4	-	I
5	hydroxyvitamin	I
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	I
18	450	I
19	monooxygenase	I
20	system	O
21	.	O

1	In	O
2	both	O
3	these	O
4	respects	O
5	,	O
6	however	O
7	,	O
8	the	O
9	DBP	B
10	mRNA	I
11	resembles	O
12	the	O
13	late	O
14	messengers	O
15	of	O
16	SV40	O
17	and	O
18	polyoma	O
19	viruses	O
20	.	O

1	Effect	O
2	of	O
3	corticosteroid	O
4	-	O
5	containing	O
6	antirheumatic	O
7	combination	O
8	drugs	O
9	on	O
10	endogenous	O
11	ACTH	B
12	and	O
13	cortisol	O
14	production	O
15	.	O

1	Serum	B
2	ACTH	I
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	metyrapone	O
10	.	O

1	Anatomy	O
2	of	O
3	the	O
4	RNA	O
5	and	O
6	gene	O
7	products	O
8	of	O
9	MC29	O
10	and	O
11	MH2	O
12	,	O
13	two	O
14	defective	O
15	avian	O
16	tumor	O
17	viruses	O
18	causing	O
19	acute	O
20	leukemia	O
21	and	O
22	carcinoma	O
23	:	O
24	evidence	O
25	for	O
26	a	O
27	new	O
28	class	O
29	of	O
30	transforming	O
31	genes	O
32	.	O

1	Bertioga	O
2	(	O
3	Guama	O
4	group	O
5	)	O
6	and	O
7	Anhembi	O
8	(	O
9	Bunyamwera	O
10	group	O
11	),	O
12	two	O
13	new	O
14	arboviruses	O
15	isolated	O
16	in	O
17	Sao	O
18	Paulo	O
19	,	O
20	Brazil	O
21	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	XXI	O
2	.	O

1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	Dopamine	B
2	receptor	I
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	V	O
2	.	O

1	A	O
2	rapid	O
3	fluorimetric	O
4	procedure	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	the	O
10	fungicide	O
11	5	O
12	-	O
13	fluorocytosine	O
14	in	O
15	serum	O
16	is	O
17	described	O
18	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	Similarly	O
2	,	O
3	maternal	B
4	serum	I
5	somatomedin	I
6	A	I
7	was	O
8	significantly	O
9	reduced	O
10	in	O
11	rats	O
12	nursing	O
13	large	O
14	litters	O
15	.	O

1	The	O
2	sequences	O
3	following	O
4	the	O
5	X	O
6	.	O
7	borealis	O
8	oocyte	O
9	and	O
10	somatic	O
11	5S	B
12	genes	I
13	are	O
14	identical	O
15	in	O
16	12	O
17	of	O
18	the	O
19	first	O
20	14	O
21	residues	O
22	and	O
23	contain	O
24	two	O
25	or	O
26	more	O
27	T	O
28	clusters	O
29	,	O
30	as	O
31	does	O
32	the	O
33	corresponding	O
34	region	O
35	of	O
36	X	B
37	.	I
38	laevis	I
39	oocyte	I
40	5S	I
41	DNA	I
42	.	O

1	This	O
2	mechanism	O
3	is	O
4	not	O
5	due	O
6	to	O
7	the	O
8	observed	O
9	grain	O
10	boundary	O
11	precipitates	O
12	.	O

1	This	O
2	report	O
3	has	O
4	reviewed	O
5	some	O
6	of	O
7	the	O
8	reasons	O
9	for	O
10	treatment	O
11	failures	O
12	and	O
13	has	O
14	presented	O
15	a	O
16	philosophy	O
17	for	O
18	their	O
19	management	O
20	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	It	O
2	seems	O
3	that	O
4	the	O
5	way	O
6	in	O
7	which	O
8	drugs	O
9	modify	O
10	a	O
11	patient	O
12	'	O
13	s	O
14	serum	O
15	chemistry	O
16	may	O
17	be	O
18	used	O
19	to	O
20	assess	O
21	the	O
22	efficacy	O
23	with	O
24	which	O
25	they	O
26	control	O
27	the	O
28	inflammatory	O
29	process	O
30	.	O

1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	B
6	alpha1AT	I
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	In	O
2	patients	O
3	who	O
4	were	O
5	not	O
6	vented	O
7	,	O
8	there	O
9	was	O
10	overall	O
11	significant	O
12	depression	O
13	of	O
14	function	O
15	(	O
16	67	O
17	+/-	O
18	5	O
19	%	O
20	of	O
21	control	O
22	;	O
23	range	O
24	,	O
25	91	O
26	--	O
27	45	O
28	%,	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	).	O

1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	A	O
2	total	O
3	of	O
4	26	O
5	BCG	O
6	strains	O
7	,	O
8	out	O
9	of	O
10	them	O
11	10	O
12	Czechoslovak	O
13	strains	O
14	(	O
15	2	O
16	lyophilized	O
17	cultures	O
18	of	O
19	BCG	O
20	of	O
21	different	O
22	batch	O
23	,	O
24	6	O
25	strains	O
26	isolated	O
27	from	O
28	abscesses	O
29	of	O
30	children	O
31	after	O
32	BCG	O
33	-	O
34	vaccination	O
35	and	O
36	2	O
37	strains	O
38	from	O
39	fatal	O
40	cases	O
41	after	O
42	BCG	O
43	-	O
44	vaccination	O
45	)	O
46	and	O
47	16	O
48	strains	O
49	obtained	O
50	from	O
51	foreign	O
52	laboratories	O
53	,	O
54	were	O
55	used	O
56	.	O

1	High	O
2	levels	O
3	of	O
4	serum	O
5	calcitonin	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O

1	Detection	O
2	of	O
3	anti	O
4	-	O
5	lymphocyte	O
6	antibodies	O
7	using	O
8	the	O
9	immunoperoxidase	B
10	antiglobulin	I
11	technic	O
12	.	O

1	The	O
2	response	O
3	of	O
4	serum	B
5	GH	I
6	to	O
7	arginine	O
8	infusion	O
9	was	O
10	normal	O
11	,	O
12	while	O
13	that	O
14	to	O
15	insulin	B
16	-	O
17	induced	O
18	hypoglycemia	O
19	was	O
20	poor	O
21	.	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	O
23	and	O
24	C3H	O
25	/	O
26	eB	O
27	origins	O
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	O
48	/	O
49	BL	O
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	O
60	,	O
61	CBA	O
62	/	O
63	LAC	O
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	O
69	).	O

1	Williams	O
2	,	O
3	2	O
4	August	O
5	1977	O
6	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Disrupted	O
2	vaccines	O
3	and	O
4	whole	O
5	-	O
6	virus	O
7	vaccines	O
8	containing	O
9	type	B
10	B	I
11	antigen	I
12	only	O
13	did	O
14	not	O
15	cause	O
16	significant	O
17	reactivity	O
18	.	O

1	255	O
2	-	O
3	61	O
4	.	O

1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O

1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	B
22	coli	I
23	endotoxin	I
24	intraperitoneally	O
25	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	The	O
2	maximum	O
3	period	O
4	of	O
5	treatment	O
6	was	O
7	73	O
8	(	O
9	oral	O
10	),	O
11	73	O
12	(	O
13	intraperitoneal	O
14	)	O
15	or	O
16	75	O
17	(	O
18	dermal	O
19	)	O
20	weeks	O
21	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	comparative	O
6	efficacy	O
7	of	O
8	diflucortolone	O
9	valerate	O
10	0	O
11	.	O
12	3	O
13	%	O
14	ointment	O
15	and	O
16	clobetasol	O
17	propionate	O
18	0	O
19	.	O
20	05	O
21	%	O
22	ointment	O
23	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Basal	O
2	FSH	B
3	and	O
4	LH	B
5	levels	O
6	were	O
7	significantly	O
8	lower	O
9	in	O
10	addicts	O
11	;	O
12	after	O
13	GnRH	B
14	stimulation	O
15	the	O
16	addicts	O
17	'	O
18	FSH	B
19	and	O
20	LH	B
21	values	O
22	increased	O
23	but	O
24	not	O
25	significantly	O
26	compared	O
27	to	O
28	controls	O
29	.	O

1	Adriamycin	O
2	:	O
3	comparison	O
4	of	O
5	a	O
6	5	O
7	-	O
8	week	O
9	schedule	O
10	with	O
11	a	O
12	3	O
13	-	O
14	week	O
15	schedule	O
16	in	O
17	the	O
18	treatment	O
19	of	O
20	breast	O
21	cancer	O
22	.	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	O
9	LH	B
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	B
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	A	O
2	randomized	O
3	clinical	O
4	trial	O
5	in	O
6	sixty	O
7	-	O
8	two	O
9	adult	O
10	patients	O
11	suffering	O
12	from	O
13	typhoid	O
14	fever	O
15	,	O
16	proved	O
17	by	O
18	blood	O
19	and	O
20	marrow	O
21	culture	O
22	,	O
23	showed	O
24	that	O
25	amoxycillin	O
26	in	O
27	a	O
28	dosage	O
29	schedule	O
30	of	O
31	1	O
32	g	O
33	8	O
34	-	O
35	hourly	O
36	orally	O
37	for	O
38	fourteen	O
39	days	O
40	was	O
41	better	O
42	than	O
43	chloramphenicol	O
44	with	O
45	regard	O
46	to	O
47	clinical	O
48	and	O
49	temperature	O
50	response	O
51	and	O
52	in	O
53	respect	O
54	of	O
55	carriers	O
56	and	O
57	relapse	O
58	rates	O
59	.	O

1	202	O
2	-	O
3	8	O
4	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	O
14	agents	O
15	(	O
16	apomorphine	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	piribedil	O
22	,	O
23	rye	O
24	-	O
25	ergot	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	pharmacological	O
38	properties	O
39	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	Thus	O
2	,	O
3	the	O
4	inhibition	O
5	of	O
6	pepsin	B
7	in	O
8	human	O
9	gastric	O
10	juice	O
11	does	O
12	not	O
13	appear	O
14	to	O
15	have	O
16	a	O
17	major	O
18	influence	O
19	on	O
20	the	O
21	healing	O
22	of	O
23	duodenal	O
24	ulcer	O
25	.	O

1	The	O
2	IDF	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	penicillin	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	sulphonamide	O
20	residues	O
21	in	O
22	milk	O
23	.	O

1	Capsular	O
2	antigens	O
3	of	O
4	Staphylococcus	O
5	aureus	O

1	The	O
2	course	O
3	of	O
4	endotoxin	O
5	fever	O
6	remained	O
7	uninfluenced	O
8	by	O
9	ALS	O
10	.	O

1	2	O
2	new	O
3	Algerian	O
4	cases	O

1	Seventy	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	patients	O
7	treated	O
8	with	O
9	ticarcillin	O
10	alone	O
11	responded	O
12	favorably	O
13	.	O

1	Accurate	O
2	pathologic	O
3	staging	O
4	identifies	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	curable	O
10	with	O
11	radiotherapy	O
12	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	Neomycin	O
2	is	O
3	fairly	O
4	effective	O
5	against	O
6	staphylococci	O
7	,	O
8	less	O
9	effective	O
10	against	O
11	streptococci	O
12	,	O
13	and	O
14	fairly	O
15	effective	O
16	against	O
17	gram	O
18	-	O
19	negative	O
20	intestinal	O
21	organisms	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O

1	2	O
2	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	Ultrasonic	O
2	evaluation	O
3	of	O
4	renal	O
5	calculi	O
6	.	O

1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Intestinal	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	B
14	renin	I
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	40	O
2	patients	O
3	with	O
4	chronic	O
5	osteomyelitis	O
6	were	O
7	treated	O
8	per	O
9	os	O
10	with	O
11	the	O
12	bactericidal	O
13	beta	O
14	-	O
15	lactam	O
16	-	O
17	antibiotic	O
18	cephalexin	O
19	during	O
20	3	O
21	to	O
22	60	O
23	weeks	O
24	.	O

1	A	O
2	total	O
3	of	O
4	57	O
5	patients	O
6	with	O
7	Hodgkin	O
8	'	O
9	s	O
10	disease	O
11	limited	O
12	to	O
13	above	O
14	the	O
15	diaphragm	O
16	(	O
17	Stages	O
18	I	O
19	and	O
20	II	O
21	,	O
22	A	O
23	and	O
24	B	O
25	)	O
26	were	O
27	treated	O
28	with	O
29	radiation	O
30	therapy	O
31	alone	O
32	at	O
33	the	O
34	University	O
35	of	O
36	Florida	O
37	between	O
38	1964	O
39	and	O
40	1974	O
41	.	O

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	As	O
2	authorized	O
3	by	O
4	the	O
5	World	O
6	Health	O
7	Organization	O
8	29th	O
9	Expert	O
10	Committee	O
11	on	O
12	Biological	O
13	Standardization	O
14	,	O
15	the	O
16	preparation	O
17	of	O
18	human	B
19	prolactin	I
20	in	O
21	ampoules	O
22	coded	O
23	75	O
24	/	O
25	504	O
26	has	O
27	been	O
28	established	O
29	as	O
30	the	O
31	International	O
32	Reference	O
33	Preparation	O
34	(	O
35	IRP	O
36	)	O
37	of	O
38	human	B
39	prolactin	I
40	for	O
41	immunoassay	O
42	.	O

1	i	O
2	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Such	O
2	marked	O
3	differences	O
4	are	O
5	found	O
6	occasionally	O
7	in	O
8	the	O
9	literature	O
10	:	O
11	heterophile	O
12	antibodies	O
13	against	O
14	bovine	B
15	gammaglobulin	I
16	are	O
17	regarded	O
18	as	O
19	responsible	O
20	for	O
21	the	O
22	interference	O
23	in	O
24	the	O
25	Sephadex	O
26	system	O
27	of	O
28	RIST	O
29	.	O

1	"	O
2	Let	O
3	the	O
4	hundred	O
5	flowers	O
6	bloom	O
7	".	O

1	Various	O
2	treatment	O
3	modalities	O
4	are	O
5	reviewed	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	psychology	O
12	as	O
13	well	O
14	as	O
15	the	O
16	physiology	O
17	of	O
18	severe	O
19	intractable	O
20	pain	O
21	.	O

1	Lethal	O
2	Tachmalcor	O
3	(	O
4	4	O
5	-(	O
6	3	O
7	'-	O
8	diethylamino	O
9	-	O
10	2	O
11	'-	O
12	hydroxypropyl	O
13	)-	O
14	ajmaline	O
15	)	O
16	poisoning	O
17	in	O
18	childhood	O

1	Ophthalmosonographic	O
2	evaluation	O
3	of	O
4	blood	O
5	flow	O
6	velocity	O
7	in	O
8	arteriocavernous	O
9	fistula	O

1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	The	O
2	systolic	O
3	pressure	O
4	gradient	O
5	(	O
6	SPG	O
7	)	O
8	between	O
9	the	O
10	left	O
11	ventricle	O
12	(	O
13	LV	O
14	)	O
15	and	O
16	left	O
17	atrium	O
18	(	O
19	LA	O
20	)	O
21	was	O
22	obtained	O
23	from	O
24	high	O
25	-	O
26	fidelity	O
27	pressure	O
28	transducers	O
29	.	O

1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O

1	The	O
2	preferential	O
3	serum	B
4	IgA	I
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	O
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O

1	A	O
2	rise	O
3	of	O
4	hemoglobin	B
5	concentration	O
6	accompanied	O
7	by	O
8	an	O
9	increase	O
10	of	O
11	the	O
12	total	O
13	iron	O
14	in	O
15	the	O
16	blood	O
17	serum	O
18	of	O
19	white	O
20	mice	O
21	was	O
22	found	O
23	under	O
24	oxygen	O
25	pressure	O
26	of	O
27	4	O
28	atm	O
29	for	O
30	an	O
31	hour	O
32	(	O
33	preconvulsive	O
34	state	O
35	)	O
36	and	O
37	6	O
38	atm	O
39	(	O
40	convulsive	O
41	state	O
42	).	O

1	Nernst	O
2	--	O
3	Planck	O
4	analog	O
5	equations	O
6	and	O
7	stationary	O
8	state	O
9	membrane	O
10	electric	O
11	potentials	O
12	.	O

1	Effects	O
2	of	O
3	methylene	O
4	chloride	O
5	,	O
6	trichloroethane	O
7	,	O
8	trichloroethylene	O
9	,	O
10	tetrachloroethylene	O
11	and	O
12	toluene	O
13	on	O
14	the	O
15	development	O
16	of	O
17	chick	O
18	embryos	O
19	.	O

1	Effect	O
2	of	O
3	intraventricular	O
4	administration	O
5	of	O
6	streptolysin	B
7	O	I
8	on	O
9	the	O
10	electroencephalogram	O
11	of	O
12	rabbits	O
13	.	O

1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	O
33	4	O
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	O
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O

1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	B
6	receptors	I
7	bordering	O
8	the	O
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	O
18	of	O
19	fentanyl	O
20	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O

1	The	O
2	major	O
3	urinary	O
4	metabolites	O
5	were	O
6	3	O
7	-(	O
8	3	O
9	-	O
10	carboxyphenyl	O
11	)-	O
12	5	O
13	-	O
14	hydroxymethyl	O
15	-	O
16	2	O
17	-	O
18	oxazolidinone	O
19	and	O
20	a	O
21	glucuronide	O
22	of	O
23	toloxatone	O
24	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	The	O
2	ventilation	O
3	did	O
4	not	O
5	increase	O
6	when	O
7	PACO2	O
8	was	O
9	increased	O
10	.	O

1	Carbohydrate	O
2	metabolism	O
3	and	O
4	the	O
5	semen	O
6	profile	O
7	:	O
8	glucose	O
9	,	O
10	insulin	B
11	,	O
12	and	O
13	sperm	O
14	studies	O
15	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	Changes	O
2	of	O
3	thirtynine	O
4	serum	O
5	protein	O
6	components	O
7	following	O
8	surgical	O
9	stress	O
10	.	O

1	These	O
2	differences	O
3	are	O
4	smaller	O
5	than	O
6	those	O
7	described	O
8	in	O
9	standard	O
10	textbooks	O
11	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	E	O
6	.	O
7	O	O
8	.	O
9	R	O
10	.	O
11	T	O
12	.	O
13	C	O
14	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	dependence	O
7	of	O
8	difference	O
9	tone	O
10	level	O
11	[	O
12	L	O
13	(	O
14	f2	O
15	-	O
16	f1	O
17	)]	O
18	on	O
19	the	O
20	following	O
21	parameters	O
22	of	O
23	the	O
24	two	O
25	-	O
26	tone	O
27	input	O
28	:	O
29	f1	O
30	,	O
31	f2	O
32	/	O
33	f1	O
34	(	O
35	f2	O
36	greater	O
37	than	O
38	f1	O
39	),	O
40	L1	O
41	,	O
42	L2	O
43	,	O
44	and	O
45	L1	O
46	=	O
47	L2	O
48	.	O

1	An	O
2	intravenous	O
3	preparation	O
4	of	O
5	doxycycline	O
6	(	O
7	DOTC	O
8	,	O
9	Vibramycin	O
10	'	O
11	Pfizer	O
12	'),	O
13	a	O
14	long	O
15	-	O
16	lasting	O
17	tetracycline	O
18	,	O
19	was	O
20	administered	O
21	mainly	O
22	by	O
23	drip	O
24	infusion	O
25	for	O
26	a	O
27	series	O
28	of	O
29	study	O
30	in	O
31	the	O
32	pediatrics	O
33	field	O
34	,	O
35	and	O
36	the	O
37	results	O
38	were	O
39	as	O
40	follows	O
41	:	O
42	1	O
43	)	O
44	DOTC	O
45	(	O
46	100	O
47	mg	O
48	)	O
49	was	O
50	dissolved	O
51	in	O
52	a	O
53	100	O
54	ml	O
55	of	O
56	glucose	O
57	solution	O
58	and	O
59	2	O
60	--	O
61	3	O
62	mg	O
63	/	O
64	kg	O
65	was	O
66	administered	O
67	intravenously	O
68	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	Structural	O
2	characteristics	O
3	of	O
4	the	O
5	erythrocyte	O
6	membrane	O
7	,	O
8	peroxidation	O
9	processes	O
10	and	O
11	antioxidant	O
12	function	O
13	in	O
14	children	O
15	with	O
16	diffuse	O
17	glomerulonephritis	O

1	The	O
2	enteric	O
3	route	O
4	is	O
5	the	O
6	principal	O
7	mode	O
8	of	O
9	transmission	O
10	for	O
11	hepatitis	O
12	A	O
13	,	O
14	but	O
15	maximal	O
16	levels	O
17	of	O
18	hepatitis	O
19	A	O
20	virus	O
21	excretion	O
22	occur	O
23	before	O
24	the	O
25	onset	O
26	of	O
27	jaundice	O
28	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	B
17	sulphatase	I
18	deficiency	O
19	.	O

1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O

1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O

1	Following	O
2	the	O
3	satisfactory	O
4	results	O
5	and	O
6	taking	O
7	into	O
8	account	O
9	that	O
10	the	O
11	complications	O
12	had	O
13	reduced	O
14	to	O
15	a	O
16	very	O
17	low	O
18	rate	O
19	(	O
20	in	O
21	2	O
22	cases	O
23	lead	O
24	tip	O
25	displacement	O
26	and	O
27	pouch	O
28	haematoma	O
29	occurred	O
30	respectively	O
31	),	O
32	the	O
33	Authors	O
34	consider	O
35	the	O
36	adopted	O
37	method	O
38	an	O
39	useful	O
40	approach	O
41	for	O
42	PMK	O
43	implantation	O
44	particularly	O
45	when	O
46	the	O
47	use	O
48	of	O
49	the	O
50	vena	O
51	cephalica	O
52	is	O
53	deemed	O
54	impossible	O
55	.	O

1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O

1	The	O
2	six	O
3	commonest	O
4	causes	O
5	of	O
6	death	O
7	varied	O
8	in	O
9	the	O
10	three	O
11	ethnic	O
12	groups	O
13	.	O

1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	"	O
42	classical	O
43	"	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Study	O
2	on	O
3	re	O
4	-	O
5	establishment	O
6	of	O
7	ovulation	O
8	after	O
9	termination	O
10	of	O
11	sex	O
12	-	O
13	steroidal	O
14	treatment	O
15	--	O
16	compared	O
17	with	O
18	re	O
19	-	O
20	appearance	O
21	of	O
22	ovulation	O
23	after	O
24	abortion	O
25	and	O
26	premature	O
27	delivery	O
28	.	O

1	Pharmacokinetics	O
2	of	O
3	Carbamazepine	O
4	in	O
5	man	O
6	:	O
7	a	O
8	review	O
9	.	O

1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	Delayed	O
2	mortality	O
3	of	O
4	mice	O
5	following	O
6	inhalation	O
7	of	O
8	acute	O
9	doses	O
10	of	O
11	CH2O	O
12	,	O
13	SO2Cl2	O
14	,	O
15	and	O
16	Br2	O
17	.	O

1	Guinea	O
2	pigs	O
3	weighing	O
4	300	O
5	approximately	O
6	350	O
7	g	O
8	were	O
9	used	O
10	.	O

1	Under	O
2	halothane	O
3	anesthesia	O
4	,	O
5	the	O
6	flow	O
7	pneumocardiogram	O
8	(	O
9	PnCG	O
10	)	O
11	and	O
12	its	O
13	time	O
14	derivative	O
15	(	O
16	acceleration	O
17	pneumocardiogram	O
18	or	O
19	dPn	O
20	/	O
21	dt	O
22	)	O
23	were	O
24	transduced	O
25	during	O
26	apnea	O
27	by	O
28	a	O
29	small	O
30	high	O
31	-	O
32	gain	O
33	pneumotachograph	O
34	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O

1	None	O
2	of	O
3	the	O
4	cystometrograms	O
5	showed	O
6	uninhibited	O
7	detrusor	O
8	contractions	O
9	.	O

1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	O
17	-	O
18	acetyldigoxin	O
19	.	O

1	Functional	O
2	effects	O
3	following	O
4	subacute	O
5	administration	O
6	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Contrary	O
2	to	O
3	1	O
4	,	O
5	8	O
6	-	O
7	dihydroxy	O
8	-	O
9	9	O
10	-	O
11	anthrone	O
12	,	O
13	1	O
14	,	O
15	8	O
16	,	O
17	9	O
18	-	O
19	triacetoxyanthracene	O
20	and	O
21	1	O
22	,	O
23	8	O
24	-	O
25	diacetoxy	O
26	-	O
27	9	O
28	-	O
29	anthrone	O
30	are	O
31	effective	O
32	against	O
33	psoriatic	O
34	lesions	O
35	without	O
36	accompanying	O
37	inflammations	O
38	of	O
39	the	O
40	skin	O
41	.	O

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O

1	We	O
2	measured	O
3	basal	O
4	plasma	O
5	prolactin	B
6	concentrations	O
7	(	O
8	in	O
9	samples	O
10	obtained	O
11	during	O
12	the	O
13	early	O
14	follicular	O
15	phase	O
16	)	O
17	in	O
18	25	O
19	normal	O
20	(	O
21	control	O
22	)	O
23	women	O
24	and	O
25	in	O
26	a	O
27	similar	O
28	group	O
29	of	O
30	40	O
31	patients	O
32	with	O
33	a	O
34	long	O
35	-	O
36	standing	O
37	history	O
38	of	O
39	infertility	O
40	.	O

1	Ovarian	O
2	allotransplantation	O
3	in	O
4	human	O
5	.	O

1	Allergic	O
2	reaction	O
3	to	O
4	Patent	O
5	Blue	O
6	Violet	O
7	during	O
8	lymphography	O
9	.	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	O
8	papio	O
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	B
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O

1	In	O
2	girls	O
3	prolactin	B
4	levels	O
5	rise	O
6	at	O
7	stage	O
8	2	O
9	,	O
10	and	O
11	are	O
12	higher	O
13	after	O
14	menarche	O
15	;	O
16	in	O
17	boys	O
18	there	O
19	is	O
20	no	O
21	change	O
22	in	O
23	prolactin	B
24	levels	O
25	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	both	O
6	of	O
7	these	O
8	surgical	O
9	procedures	O
10	were	O
11	as	O
12	effective	O
13	as	O
14	pinealectomy	O
15	in	O
16	reversing	O
17	the	O
18	pineal	O
19	-	O
20	induced	O
21	alterations	O
22	in	O
23	the	O
24	reproductive	O
25	physiology	O
26	of	O
27	the	O
28	blind	O
29	-	O
30	anosmic	O
31	female	O
32	rat	O
33	.	O

1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O

1	Such	O
2	an	O
3	hemoglobin	B
4	solution	O
5	was	O
6	shown	O
7	to	O
8	exhibit	O
9	a	O
10	high	O
11	affinity	O
12	for	O
13	oxygen	O
14	and	O
15	a	O
16	low	O
17	Bohr	O
18	effect	O
19	(	O
20	assessed	O
21	from	O
22	the	O
23	delta	O
24	log	O
25	Po2	O
26	/	O
27	delta	O
28	pH	O
29	ratio	O
30	).	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	O
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O

1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	contrary	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	observers	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O

1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O

1	Vitrectomy	O
2	in	O
3	ocular	O
4	traumatology	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	No	O
2	systematic	O
3	L	O
4	-	O
5	R	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	B
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	Deep	O
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	O
8	possessing	O
9	the	O
10	type	O
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O

1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O

1	Smoking	O
2	was	O
3	regarded	O
4	as	O
5	the	O
6	major	O
7	contribution	O
8	to	O
9	pulmonary	O
10	dysfunction	O
11	.	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O

1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O

1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O

1	Evaluation	O
2	of	O
3	the	O
4	Du	O
5	Pont	O
6	aca	O
7	ammonia	O
8	procedure	O
9	.	O

1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O

1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O

1	Kodak	O
2	XV	O
3	-	O
4	2	O
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	O
6	renin	B
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	Cortisone	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	clearing	O
11	agents	O
12	.	O

1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	sharing	O
7	principle	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	Delayed	O
2	hypersensitivity	O
3	in	O
4	man	O
5	:	O
6	effects	O
7	of	O
8	systemic	O
9	anticoagulation	O
10	.	O

1	In	O
2	three	O
3	of	O
4	the	O
5	seven	O
6	,	O
7	inhalation	O
8	of	O
9	2	O
10	ml	O
11	normal	O
12	saline	O
13	produced	O
14	FEV1	O
15	falls	O
16	of	O
17	25	O
18	%	O
19	to	O
20	30	O
21	%,	O
22	but	O
23	these	O
24	falls	O
25	were	O
26	not	O
27	as	O
28	great	O
29	as	O
30	each	O
31	subject	O
32	'	O
33	s	O
34	reactions	O
35	to	O
36	the	O
37	test	O
38	solutions	O
39	.	O

1	Experimental	O
2	studies	O
3	on	O
4	virus	O
5	excretion	O
6	and	O
7	non	O
8	-	O
9	arthropod	O
10	transmission	O
11	.	O

1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	O
9	superoxide	B
10	dismutase	I
11	.	O

1	Measurement	O
2	of	O
3	magnesium	O
4	absorption	O
5	in	O
6	man	O
7	using	O
8	stable	O
9	26Mg	O
10	as	O
11	a	O
12	tracer	O
13	.	O

1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O

1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O

1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O

1	Escherichia	O
2	of	O
3	a	O
4	single	O
5	sero	O
6	-	O
7	anzymatic	O
8	type	O
9	(	O
10	06a6b	O
11	:	O
12	K13	O
13	:	O
14	H1	O
15	)	O
16	were	O
17	isolated	O
18	in	O
19	a	O
20	group	O
21	affection	O
22	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Analysis	O
2	of	O
3	liver	O
4	biopsy	O
5	specimens	O
6	from	O
7	patients	O
8	with	O
9	hepatitis	O
10	showed	O
11	a	O
12	large	O
13	variation	O
14	in	O
15	the	O
16	mean	O
17	iron	O
18	content	O
19	of	O
20	the	O
21	liver	O
22	ferritin	B
23	molecules	O
24	.	O

1	Female	O
2	mice	O
3	were	O
4	significantly	O
5	more	O
6	resistant	O
7	to	O
8	infection	O
9	than	O
10	males	O
11	.	O

1	During	O
2	the	O
3	following	O
4	9	O
5	1	O
6	/	O
7	2	O
8	years	O
9	three	O
10	sequential	O
11	liver	O
12	biopsies	O
13	were	O
14	performed	O
15	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O

1	Silicosis	O
2	mortality	O

1	These	O
2	consisted	O
3	of	O
4	beading	O
5	and	O
6	strictures	O
7	mainly	O
8	of	O
9	the	O
10	intrahepatic	O
11	biliary	O
12	tree	O
13	(	O
14	IHB	O
15	).	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	Thromboplastic	O
2	and	O
3	fibrynolytic	O
4	activity	O
5	of	O
6	the	O
7	blood	O
8	after	O
9	administration	O
10	of	O
11	intralipid	O
12	in	O
13	men	O
14	with	O
15	history	O
16	of	O
17	myocardial	O
18	infarction	O
19	up	O
20	to	O
21	45	O
22	year	O
23	of	O
24	life	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	pure	O
5	natural	O
6	porcine	B
7	secretin	I
8	on	O
9	endocrine	O
10	and	O
11	exocrine	O
12	pancreatic	O
13	secretion	O
14	was	O
15	studied	O
16	in	O
17	the	O
18	totally	O
19	isolated	O
20	perfused	O
21	porcine	O
22	pancreas	O
23	.	O

1	Biometric	O
2	analysis	O
3	of	O
4	intraocular	O
5	lens	O
6	power	O
7	required	O
8	to	O
9	produce	O
10	emmetropia	O
11	:	O
12	results	O
13	of	O
14	450	O
15	implants	O
16	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	99mTc	O
2	phytate	O
3	,	O
4	198Au	O
5	colloid	O
6	,	O
7	and	O
8	99mTc	O
9	antimony	O
10	sulfide	O
11	have	O
12	been	O
13	used	O
14	;	O
15	the	O
16	last	O
17	appears	O
18	to	O
19	have	O
20	been	O
21	the	O
22	most	O
23	satisfactory	O
24	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	B
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	A	O
2	sharp	O
3	outbreak	O
4	of	O
5	influenza	O
6	A	O
7	occurred	O
8	on	O
9	the	O
10	base	O
11	during	O
12	February	O
13	that	O
14	was	O
15	due	O
16	to	O
17	an	O
18	A	O
19	/	O
20	Texas	O
21	/	O
22	1	O
23	/	O
24	77	O
25	-	O
26	like	O
27	virus	O
28	,	O
29	a	O
30	variant	O
31	of	O
32	the	O
33	A	O
34	/	O
35	Victoria	O
36	/	O
37	3	O
38	/	O
39	75	O
40	prototpye	O
41	.	O

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	A	O
2	one	O
3	-	O
4	way	O
5	analysis	O
6	of	O
7	variance	O
8	,	O
9	performed	O
10	separately	O
11	for	O
12	men	O
13	and	O
14	women	O
15	for	O
16	differences	O
17	among	O
18	the	O
19	three	O
20	phobic	O
21	groups	O
22	on	O
23	field	O
24	dependence	O
25	,	O
26	showed	O
27	significance	O
28	(	O
29	rho	O
30	less	O
31	than	O
32	.	O
33	05	O
34	)	O
35	for	O
36	the	O
37	females	O
38	,	O
39	with	O
40	the	O
41	famale	O
42	agoraphobic	O
43	being	O
44	more	O
45	field	O
46	dependent	O
47	than	O
48	the	O
49	female	O
50	simple	O
51	phobic	O
52	groups	O
53	,	O
54	but	O
55	not	O
56	for	O
57	the	O
58	males	O
59	.	O

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	O
13	11	O
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	The	O
2	calculated	O
3	pD2	O
4	values	O
5	were	O
6	8	O
7	.	O
8	8	O
9	for	O
10	E	O
11	,	O
12	8	O
13	.	O
14	6	O
15	for	O
16	DHE	O
17	and	O
18	6	O
19	.	O
20	6	O
21	for	O
22	M	O
23	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	B
10	beta	I
11	receptor	I
12	blockader	O
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	Orthop	O
2	.	O

1	Thyroid	O
2	disease	O
3	and	O
4	pregnancy	O
5	.	O

1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O

1	To	O
2	minimize	O
3	reflux	O
4	into	O
5	the	O
6	blind	O
7	loop	O
8	,	O
9	a	O
10	number	O
11	of	O
12	technical	O
13	steps	O
14	are	O
15	considered	O
16	indispensable	O
17	:	O
18	1	O
19	)	O
20	fluted	O
21	section	O
22	of	O
23	the	O
24	jejunal	O
25	stump	O
26	;	O
27	2	O
28	)	O
29	isoperistaltic	O
30	construction	O
31	of	O
32	the	O
33	anastomosis	O
34	and	O
35	,	O
36	particularly	O
37	,	O
38	3	O
39	)	O
40	the	O
41	creation	O
42	of	O
43	a	O
44	single	O
45	or	O
46	double	O
47	valve	O
48	system	O
49	upstream	O
50	from	O
51	the	O
52	anastomosis	O
53	by	O
54	spiral	O
55	introflexion	O
56	of	O
57	the	O
58	mucosa	O
59	using	O
60	seroserous	O
61	stitches	O
62	parallel	O
63	and	O
64	perpendicular	O
65	to	O
66	the	O
67	ileal	O
68	lumen	O
69	.	O

1	At	O
2	this	O
3	stage	O
4	,	O
5	the	O
6	eventual	O
7	high	O
8	mortality	O
9	of	O
10	acute	O
11	ischemia	O
12	is	O
13	established	O
14	whatever	O
15	the	O
16	urgency	O
17	of	O
18	the	O
19	operation	O
20	or	O
21	the	O
22	skill	O
23	with	O
24	which	O
25	it	O
26	is	O
27	performed	O
28	.	O

1	Pathogens	O
2	(	O
3	Staphylococcus	O
4	aureus	O
5	or	O
6	Gram	O
7	-	O
8	negative	O
9	bacilli	O
10	)	O
11	were	O
12	isolated	O
13	from	O
14	only	O
15	one	O
16	member	O
17	of	O
18	staff	O
19	in	O
20	small	O
21	numbers	O
22	and	O
23	irregularly	O
24	and	O
25	rarely	O
26	in	O
27	large	O
28	numbers	O
29	from	O
30	patients	O
31	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	A	O
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O

1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O

1	Serum	B
2	relaxin	I
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O

1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O

1	Contingency	O
2	contracting	O
3	between	O
4	clients	O
5	and	O
6	their	O
7	parents	O
8	/	O
9	caregivers	O
10	was	O
11	used	O
12	to	O
13	specify	O
14	consequences	O
15	for	O
16	daily	O
17	self	O
18	-	O
19	monitoring	O
20	,	O
21	reduced	O
22	caloric	O
23	intake	O
24	,	O
25	weight	O
26	loss	O
27	,	O
28	and	O
29	exercise	O
30	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	The	O
2	results	O
3	of	O
4	a	O
5	quantitative	O
6	study	O
7	of	O
8	vasculosyncytial	O
9	membranes	O
10	in	O
11	123	O
12	placentas	O
13	are	O
14	presented	O
15	.	O

1	The	O
2	micromethod	O
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	O
15	.	O

1	Platelet	O
2	serotonin	O
3	(	O
4	5	O
5	-	O
6	HT	O
7	)	O
8	and	O
9	5	B
10	-	I
11	HT	I
12	releasing	I
13	factor	I
14	in	O
15	plasma	O
16	of	O
17	migrainous	O
18	patients	O
19	.	O

1	The	O
2	overall	O
3	incidence	O
4	of	O
5	SIDS	O
6	was	O
7	1	O
8	.	O
9	43	O
10	per	O
11	1	O
12	,	O
13	000	O
14	live	O
15	births	O
16	.	O

1	The	O
2	vigilance	O
3	task	O
4	and	O
5	the	O
6	measurement	O
7	of	O
8	attentional	O
9	deficits	O
10	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O

1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O

1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	Carcinoembryonic	B
2	antigen	I
3	(	O
4	CEA	B
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	We	O
2	remain	O
3	convinced	O
4	that	O
5	antilymphocyte	B
6	globulin	I
7	(	O
8	ALG	B
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	global	O
7	assessment	O
8	patients	O
9	showed	O
10	a	O
11	highly	O
12	significant	O
13	preference	O
14	for	O
15	imipramine	O
16	compared	O
17	with	O
18	placebo	O
19	as	O
20	adjunctive	O
21	therapy	O
22	.	O

1	39	O
2	-	O
3	47	O
4	.	O

1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	"	O
23	cured	O
24	"	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	Advances	O
2	in	O
3	the	O
4	management	O
5	of	O
6	gynecologic	O
7	cancer	O
8	--	O
9	radiation	O
10	therapy	O
11	.	O

1	The	O
2	clinico	O
3	-	O
4	pathological	O
5	data	O
6	from	O
7	a	O
8	patient	O
9	with	O
10	irreversible	O
11	post	O
12	-	O
13	partum	O
14	renal	O
15	failure	O
16	(	O
17	IPRF	O
18	)	O
19	are	O
20	presented	O
21	.	O

1	Personal	O
2	satisfaction	O
3	in	O
4	nursing	O
5	:	O
6	an	O
7	encounter	O
8	with	O
9	extremely	O
10	hostile	O
11	patients	O

1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O

1	19	O
2	-	O
3	32	O
4	.	O

1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	The	O
2	effect	O
3	of	O
4	hydrostatic	O
5	pressure	O
6	on	O
7	the	O
8	swimming	O
9	activity	O
10	of	O
11	three	O
12	hyponeustonic	O
13	crustacea	O
14	,	O
15	Anomalocera	O
16	patersoni	O
17	,	O
18	Pontella	O
19	mediterranea	O
20	,	O
21	Labidocera	O
22	wollastoni	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Deflunia	O
2	was	O
3	well	O
4	tolerated	O
5	by	O
6	25	O
7	patients	O
8	,	O
9	very	O
10	well	O
11	tolerated	O
12	by	O
13	2	O
14	.	O

1	III	O
2	.	O

1	A	O
2	new	O
3	instrument	O
4	has	O
5	been	O
6	designed	O
7	for	O
8	freeze	O
9	-	O
10	fracturing	O
11	of	O
12	biological	O
13	material	O
14	in	O
15	ultra	O
16	high	O
17	vacuum	O
18	.	O

1	Pancreatic	O
2	and	O
3	biliary	O
4	secretion	O
5	and	O
6	gastric	O
7	emptying	O
8	rates	O
9	of	O
10	a	O
11	liquid	O
12	test	O
13	meal	O
14	(	O
15	LTM	O
16	)	O
17	were	O
18	determined	O
19	in	O
20	normal	O
21	persons	O
22	,	O
23	in	O
24	patients	O
25	with	O
26	subtotal	O
27	gastrectomy	O
28	with	O
29	gastroduodenostomy	O
30	(	O
31	STG	O
32	-	O
33	BI	O
34	)	O
35	or	O
36	with	O
37	gastrojejunostomy	O
38	(	O
39	STG	O
40	-	O
41	BII	O
42	),	O
43	and	O
44	in	O
45	patients	O
46	with	O
47	truncal	O
48	vagotomy	O
49	and	O
50	pyloroplasty	O
51	(	O
52	V	O
53	&	O
54	P	O
55	).	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	O
24	"	O
25	OFF	O
26	"	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	If	O
2	,	O
3	however	O
4	,	O
5	the	O
6	mean	O
7	temperature	O
8	rise	O
9	was	O
10	higher	O
11	(	O
12	0	O
13	.	O
14	57	O
15	degrees	O
16	C	O
17	or	O
18	0	O
19	.	O
20	69	O
21	degrees	O
22	C	O
23	),	O
24	such	O
25	a	O
26	selection	O
27	practically	O
28	resulted	O
29	in	O
30	the	O
31	disappearance	O
32	of	O
33	'	O
34	passable	O
35	'	O
36	qualifications	O
37	in	O
38	the	O
39	triplet	O
40	groups	O
41	and	O
42	a	O
43	great	O
44	predominance	O
45	of	O
46	'	O
47	to	O
48	be	O
49	rejected	O
50	'	O
51	qualifications	O
52	in	O
53	the	O
54	large	O
55	groups	O
56	.	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	Selective	O
2	bronchial	O
3	intubation	O
4	in	O
5	the	O
6	management	O
7	of	O
8	unilateral	O
9	pulmonary	O
10	interstitial	O
11	emphysema	O
12	.	O

1	The	O
2	background	O
3	processes	O
4	depending	O
5	on	O
6	the	O
7	etiological	O
8	factor	O
9	and	O
10	the	O
11	character	O
12	of	O
13	lesion	O
14	of	O
15	the	O
16	epithelium	O
17	are	O
18	divided	O
19	into	O
20	dyshormonal	O
21	,	O
22	inflammatory	O
23	,	O
24	and	O
25	posttraumatic	O
26	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	O
15	.	O
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	Current	O
2	diagnostic	O
3	uses	O
4	of	O
5	computerized	O
6	tomography	O
7	in	O
8	clinical	O
9	medicine	O
10	.	O

1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	Recurrence	O
2	of	O
3	bladder	O
4	tumors	O
5	among	O
6	the	O
7	original	O
8	9	O
9	cases	O
10	has	O
11	occurred	O
12	only	O
13	among	O
14	the	O
15	5	O
16	whose	O
17	properdin	B
18	levels	O
19	remained	O
20	below	O
21	the	O
22	median	O
23	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	Dangers	O
2	in	O
3	use	O
4	of	O
5	live	O
6	-	O
7	virus	O
8	vaccines	O
9	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	B
6	activators	O
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	O
14	-	O
15	1	O
16	-	O
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O

1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O

1	The	O
2	data	O
3	normally	O
4	available	O
5	are	O
6	insufficient	O
7	and	O
8	take	O
9	no	O
10	account	O
11	of	O
12	the	O
13	direction	O
14	of	O
15	recirculation	O
16	,	O
17	which	O
18	may	O
19	be	O
20	a	O
21	determining	O
22	factor	O
23	.	O

1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O

1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	O
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O

1	The	O
2	acids	O
3	were	O
4	obtained	O
5	by	O
6	hydrolysis	O
7	of	O
8	the	O
9	corresponding	O
10	esters	O
11	,	O
12	and	O
13	their	O
14	anti	O
15	-	O
16	inflammatory	O
17	activity	O
18	was	O
19	tested	O
20	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	Serum	B
2	amylase	I
3	became	O
4	markedly	O
5	elevated	O
6	(	O
7	2	O
8	,	O
9	624	O
10	CU	O
11	/	O
12	100	O
13	ml	O
14	),	O
15	as	O
16	did	O
17	the	O
18	serum	O
19	FFA	O
20	(	O
21	29	O
22	.	O
23	19	O
24	mEq	O
25	/	O
26	liter	O
27	).	O

1	In	O
2	the	O
3	control	O
4	preparation	O
5	before	O
6	weight	O
7	was	O
8	allowed	O
9	to	O
10	increase	O
11	,	O
12	isogravimetric	O
13	capillary	O
14	pressure	O
15	(	O
16	Pci	O
17	)	O
18	averaged	O
19	8	O
20	mmHg	O
21	lower	O
22	than	O
23	colloid	O
24	osmotic	O
25	pressure	O
26	of	O
27	the	O
28	plasma	O
29	(	O
30	IIp	O
31	).	O

1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O

1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	B
21	Lytic	I
22	Factor	I
23	and	O
24	Phospholipase	B
25	-	I
26	A	I
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O

1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	The	O
2	length	O
3	scales	O
4	of	O
5	the	O
6	turbulence	O
7	were	O
8	also	O
9	estimated	O
10	:	O
11	at	O
12	a	O
13	Reynolds	O
14	number	O
15	near	O
16	4	O
17	,	O
18	000	O
19	the	O
20	macroscale	O
21	is	O
22	about	O
23	1	O
24	.	O
25	25	O
26	mm	O
27	,	O
28	the	O
29	Taylor	O
30	microscale	O
31	is	O
32	about	O
33	0	O
34	.	O
35	85	O
36	mm	O
37	,	O
38	and	O
39	the	O
40	Kolmogoroff	O
41	scale	O
42	is	O
43	near	O
44	0	O
45	.	O
46	075	O
47	mm	O
48	.	O

1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	No	O
2	hypotension	O
3	was	O
4	noted	O
5	in	O
6	patients	O
7	with	O
8	toxemia	O
9	and	O
10	only	O
11	2	O
12	ran	O
13	a	O
14	fever	O
15	above	O
16	37	O
17	.	O
18	5	O
19	degrees	O
20	C	O
21	.	O
